Tower Research Capital LLC TRC boosted its holdings in Chemed Co. (NYSE:CHE) by 303.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,194 shares of the company’s stock after buying an additional 1,650 shares during the period. Tower Research Capital LLC TRC’s holdings in Chemed were worth $701,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of CHE. Bank of Montreal Can lifted its holdings in shares of Chemed by 43.3% in the second quarter. Bank of Montreal Can now owns 7,064 shares of the company’s stock worth $2,273,000 after buying an additional 2,136 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Chemed by 10.9% in the second quarter. Crossmark Global Holdings Inc. now owns 2,689 shares of the company’s stock worth $865,000 after purchasing an additional 264 shares during the last quarter. New Mexico Educational Retirement Board bought a new position in shares of Chemed in the second quarter worth about $1,191,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Chemed during the 2nd quarter worth about $644,000. Finally, First Trust Advisors LP grew its holdings in Chemed by 22.7% during the 2nd quarter. First Trust Advisors LP now owns 17,348 shares of the company’s stock worth $5,583,000 after acquiring an additional 3,213 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on CHE shares. Bank of America started coverage on shares of Chemed in a report on Friday, October 12th. They set a “buy” rating and a $390.00 target price on the stock. Zacks Investment Research cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $332.00.

NYSE:CHE opened at $304.90 on Friday. Chemed Co. has a fifty-two week low of $234.00 and a fifty-two week high of $335.99. The stock has a market capitalization of $4.85 billion, a PE ratio of 56.88, a PEG ratio of 2.66 and a beta of 1.18. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23.

Chemed (NYSE:CHE) last released its quarterly earnings results on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.80 by $0.27. Chemed had a net margin of 11.73% and a return on equity of 35.13%. The business had revenue of $444.15 million for the quarter, compared to analysts’ expectations of $445.16 million. During the same period last year, the business earned $2.15 EPS. The company’s revenue was up 6.4% compared to the same quarter last year. As a group, equities research analysts forecast that Chemed Co. will post 11.41 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Stockholders of record on Monday, November 12th were issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend was Thursday, November 8th. Chemed’s dividend payout ratio is currently 22.39%.

In other news, insider David Patrick Williams sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $302.30, for a total value of $3,023,000.00. Following the sale, the insider now directly owns 24,918 shares in the company, valued at approximately $7,532,711.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Spencer S. Lee sold 657 shares of the stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $311.30, for a total transaction of $204,524.10. Following the completion of the transaction, the executive vice president now directly owns 31,258 shares of the company’s stock, valued at $9,730,615.40. The disclosure for this sale can be found here. Insiders sold a total of 24,953 shares of company stock worth $7,678,463 over the last 90 days. Company insiders own 4.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Chemed Co. (CHE) Shares Bought by Tower Research Capital LLC TRC” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at

Chemed Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Featured Article: Float

Want to see what other hedge funds are holding CHE? Visit to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with's FREE daily email newsletter.